Mechanisms of resistance to EGFR tyrosine kinase inhibitors - ScienceDirect
YES1 amplification is a mechanism of acquired resistance to EGFR inhibitors identified by transposon mutagenesis and clinical genomics | PNAS
New Strategies in Overcoming Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Lung Cancer | Clinical Cancer Research
Figure 2 from Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in EGFR-mutant non-small cell lung cancer: a new era begins. | Semantic Scholar
Mechanisms of osimertinib resistance and emerging treatment options - Lung Cancer
HER3 and mutant EGFR meet MET | Nature Medicine
Diagnostics of EGFR-mutant disease: biomarkers with significant clinical implications - memoinOncology
EGFR-independent mechanisms of acquired resistance to AZD9291 in EGFR T790M-positive NSCLC patients - Annals of Oncology
HCC827 GR cells are resistant to gefitinib in vitro and show MET... | Download Scientific Diagram
MET amplification results in heterogeneous responses to osimertinib in EGFR‐mutant lung cancer treated with erlotinib - Nishiyama - 2020 - Cancer Science - Wiley Online Library
Hepatocyte Growth Factor Expression in EGFR Mutant Lung Cancer with Intrinsic and Acquired Resistance to Tyrosine Kinase Inhibitors in a Japanese Cohort - Journal of Thoracic Oncology
Afatinib/Cetuximab in EGFR TKI-Resistant NSCLC
The clinical efficacy of combinatorial therapy of EGFR-TKI and crizotinib in overcoming MET amplification-mediated resistance from prior EGFR-TKI therapy - Lung Cancer
Mechanisms of resistance to EGFR tyrosine kinase inhibitors - ScienceDirect
MET/HGF pathway activation as a paradigm of resistance to targeted therapies - Ko - Annals of Translational Medicine
Molecular mechanisms of acquired resistance to third-generation EGFR-TKIs in EGFR T790M-mutant lung cancer - Annals of Oncology
Does c-Met remain a rational target for therapy in patients with EGFR TKI- resistant non-small cell lung cancer? - Cancer Treatment Reviews
Reciprocal and Complementary Role of MET Amplification and EGFR T790M Mutation in Acquired Resistance to Kinase Inhibitors in Lung Cancer | Clinical Cancer Research
EMT, MET amplification, and IGF-1R confer resistance to EGFR TKIs.... | Download Scientific Diagram
The mechanism of acquired resistance to epidermal growth factor... | Download Scientific Diagram
Resistance mechanisms to osimertinib in EGFR -mutated non-small cell lung cancer | British Journal of Cancer
![Mechanisms of acquired resistance to osimertinib [32-36]. EGFR,... | Download Scientific Diagram](https://www.researchgate.net/publication/328978288/figure/fig2/AS:693427310178304@1542337362022/Mechanisms-of-acquired-resistance-to-osimertinib-32-36-EGFR-epidermal-growth-factor.png "Mechanisms of acquired resistance to osimertinib [32-36]. EGFR,... | Download Scientific Diagram")
Mechanisms of acquired resistance to osimertinib [32-36]. EGFR,... | Download Scientific Diagram
Overview of probable resistance mechanisms in EGFR-TKI afatinib.... | Download Scientific Diagram
Strategies to Overcome Bypass Mechanisms Mediating Clinical Resistance to EGFR Tyrosine Kinase Inhibition in Lung Cancer | Molecular Cancer Therapeutics
11 Terapias dirigidas Cáncer de Pulmón
MET inhibitors for targeted therapy of EGFR TKI-resistant lung cancer | Journal of Hematology & Oncology | Full Text
Cells | Free Full-Text | Mechanism of Resistance to Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors and a Potential Treatment Strategy | HTML
